ArticleTrials2025
Effect of neutropenic diet with or without magnesium supplementation on inflammatory factors and outcomes of allogeneic hematopoietic stem cell transplantation in patients with acute leukemia: study protocol for a randomized clinical trial.
Article in Trials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe management of transplantation-related complications in acute leukemia patients has become increasingly important at the bedside. Limited clinical investigations have been conducted regarding high-dose oral magnesium supplementation. In this study, the effects of oral magnesium citrate will be investigated. Magnesium's role in preventing adverse transplantation outcomes, including graft-versus-host disease (GVHD), will be examined through its inhibitory effects on inflammatory pathways and cytokine production.
methodsThis randomized, double-blind clinical trial will be conducted at Taleghani Hospital in Tehran, Iran. Fifty patients admitted to the bone marrow transplantation ward will be enrolled based on eligibility criteria. Participants will be randomly allocated using permuted block randomization into two groups (n = 25 each): neutropenic diet with magnesium supplementation or neutropenic diet with placebo. In the intervention and placebo groups, 420 mg of magnesium citrate or placebo will be administered for 3 weeks, respectively. Patient assessment will be conducted using consent forms, general questionnaires, three-day 24-h food recalls, and laboratory tests including inflammatory factors such as Interleukin-6 (IL-6), Tumor necrosis factor-alpha (TNF-α), Erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP). Statistical analysis will be performed based on the intention-to-treat principle. DISCUSSION: This protocol aims to be one of the first to implement an oral magnesium supplementation program in a double-blind randomized controlled trial, assessing both inflammatory markers and clinical outcomes in acute leukemia patients undergoing Allo-HSCT.
trial registrationIranian Registry of Clinical Trials. IRCT20240812062726N1. URL of trial registry record: https://irct.behdasht.gov.ir/trial/78589 . Registered on 17 September 2024.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.